FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Sinha Vikas						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN								5. Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify				/ner
(Last) (First) (Middle) C/O ALEXION PHARMACUETICALS, INC. 352 KNOTTER DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 11/03/2010								A below)	SVP	& CF	below)	
(Street) CHESHIRE CT 06410					_ 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)	n Dori		- Ca		tion As		Dia	nagad a	of or Do	noficial	l. O. mad	<u> </u>			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa	3. Transaction Code (Instr.		ties Acquire Of (D) (Inst	d (A) or	5. Amount of Securities Beneficially Owned Followin		Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	orted saction(s) tr. 3 and 4)			(Instr. 4)
Common Stock, par value \$.0001 per share 11/03/						2010			М		20,000	(1) A	\$13.7	89,281			D	
Common Stock, par value \$.0001 per share 11/03/					3/2010	2010			S		20,000	(1) D	\$70	69	69,281		D	
Common Stock, par value \$.0001 per share 11/03/2					3/2010	2010			М		4,000) A \$10		5 73	73,281		D	
		-									osed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed Date,	4. Transaction Code (Instr 8)		5. Number n of		6. Date Exercisa Expiration Date (Month/Day/Yea		sable and e	ble and 7. Title and of Securitie		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Option to Purchase Common Stock	\$13.79	11/03/2010			S			20,000	12/21/20	005	09/21/2015	Common Stock, par value \$.0001 per share	20,000	\$0	0 60,000		D	
Option to Purchase Common Stock	\$16.35	11/03/2010			S			4,000	09/07/20	006	06/07/2016	Common Stock, par value \$.0001 per share	4,000	\$0	4,000)	D	

Explanation of Responses:

1. The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1 (c)(1) of the Securities Exchange Act.

/s/ Vikas Sinha

11/05/2010

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.